Getein Biotech

Getein Biotech OCF/Debt

The Operating Cash Flow to Debt Ratio of Getein Biotech (603387.SS) as of Nov 9, 2026 is 73.29 %. In the previous year, Operating Cash Flow to Debt Ratio was 51.74 % — a change of 41.63% (higher).

OCF/Debt

73.29 %

YoY

41.63%

Last updated:

Operating Cash Flow to Debt Ratio of Getein Biotech is 2024 73.29 % . Operating Cash Flow to Debt Ratio of Getein Biotech was 2023 51.74 % . It decreases by 41.63% higher compared to the previous year.

The Getein Biotech OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
598.95 CNY
Jan 1, 2019
237.61 CNY
Jan 1, 2020
48.20 CNY
Jan 1, 2021
87.09 CNY
Jan 1, 2022
81.72 CNY
Jan 1, 2023
51.74 CNY
Jan 1, 2024
73.29 CNY
The Getein Biotech OCF/Debt history
YEAROCF/DebtYoY
73.29 %+41.63%
51.74 %-36.68%
81.72 %-6.17%
87.09 %+80.68%
48.20 %-79.71%
237.61 %-60.33%
598.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc generates revenue through the sale of in vitro diagnostic reagents and diagnostic instruments. The company offers POCT reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. Diagnostic instruments include the FIA 8000 and FIA 8600 immunoquantitative analyzers, Getein 1100 and Getein 1180 fluorescence immunoquantitative analyzers, CM 400 automatic biochemical analyzer, MAGICL 6000 automatic chemiluminescence analyzer, and BHA-5000 five classification blood cell analyzer. The firm also provides testing and agency services. Products are distributed domestically and to overseas markets. The primary buyers of Getein Biotech's products include healthcare facilities, laboratories, and medical institutions within China and international markets. Domestic sales focus on the Chinese healthcare sector, while overseas markets extend to global customers seeking diagnostic solutions. The company's reagent and instrument portfolio targets hospitals, clinics, and diagnostic centers requiring reliable testing equipment and consumables. Getein Biotech's revenue streams are derived from direct sales of its diagnostic reagents and instruments, as well as service-based offerings like testing and agency services. The company's product range caters to both domestic and international healthcare providers, with a strong emphasis on in vitro diagnostic solutions for blood analysis, chemiluminescence, and biochemical testing. The firm's distribution strategy ensures its products reach medical facilities across China and internationally. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

Operating Cash Flow to Debt Ratio of Getein Biotech is 73.29 % in 2024.

Operating Cash Flow to Debt Ratio of Getein Biotech changed from 51.74 % to 73.29 %, representing a 41.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Getein Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Getein Biotech

All Key Metrics — Getein Biotech